Compare CTGO & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | FBRX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.3M | 487.2M |
| IPO Year | 2010 | 2017 |
| Metric | CTGO | FBRX |
|---|---|---|
| Price | $14.64 | $18.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $41.00 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 667.9K | 243.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.77 | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.88 | $9.12 |
| 52 Week High | $34.38 | $35.80 |
| Indicator | CTGO | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 44.08 |
| Support Level | N/A | $17.33 |
| Resistance Level | $29.54 | $22.84 |
| Average True Range (ATR) | 1.03 | 1.22 |
| MACD | -0.01 | 0.46 |
| Stochastic Oscillator | 2.89 | 83.14 |
Contango Silver & Gold Inc, formerly Contango Ore Inc operates in the United States. The company is engaged in the exploration for and development of gold ore and associated minerals in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin, whose governmental entity is the Tetlin Tribal Council, for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.